Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus TARPEYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus TARPEYO.
KENALOG IN ORABASE vs TARPEYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
TARPEYO (budesonide) is a corticosteroid with anti-inflammatory activity. It acts by binding to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and immune cell activation, thereby reducing proteinuria in IgA nephropathy.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
16 mg/kg intravenously once daily on Days 1-5 of each 28-day cycle.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life is approximately 27.3 hours (range 21-36 hours) in patients with IgA nephropathy. This supports once-weekly subcutaneous dosing without dose adjustment over the dosing interval.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily hepatic metabolism, with <1% excreted unchanged in urine and <1% in feces. Elimination is predominantly via biliary excretion of metabolites into feces, accounting for >90% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid